| Availability: | |
|---|---|
NeoSkin/NeoEye
PNPURE™
Among global polynucleotide treatment brands, PNPURE™ stands out as a high-purity, medical-grade injectable skin booster designed for deep dermal regeneration, extracellular matrix (ECM) restoration, and structural hydration.
Formulated with high-molecular-weight polynucleotides (1260–1570 kDa) derived from sustainably sourced Pacific salmon DNA and refined through the proprietary PUNEXT™ multi-stage purification, PNPURE™ pn injection delivers reliable biocompatibility (raw material DNA similarity to human DNA ~98%) and production purity (>99% PN) that together support robust tissue regeneration while minimising antigenic risk.
To assist clinics and distributors in protocol planning, the PNPURE™ product family is formulated into two distinct concentrations tailored for specific anatomical depths and clinical indications:
| Technical Parameter | PNPURE™ NeoSkin (Full-Face & Body) | PNPURE™ NeoEye (Periocular Zone) |
| Primary Indication | Full-face dermal rejuvenation, scarring, severe laxity | Tear troughs, periorbital fine lines, dark circles |
| Active PN Concentration | 25 mg/mL (2.5% Pure PN) | 10 mg/mL (1.0% Pure PN) |
| Synergistic Actives | Pure High-MW Polynucleotides | Hyaluronic Acid, Amino Acid Complex, Carnosine |
| Molecular Weight | 1260–1570 kDa | 1260–1570 kDa |
| Injection Depth | Mid-to-deep dermis | Superficial-to-mid dermis / Periorbital plane |
| Packaging & Needle | 3 mL Prefilled Syringe / 30G Needle | 1 mL Prefilled Syringe / 30G Needle |
| Target Clinical Result | Matrix reconstruction, firmness, deep hydration | Periorbital brightening, skin thickening, fine line smoothing |

Polynucleotides (PN) act as biologically active scaffolds that modulate the dermal microenvironment. PNPURE™ leverages 3 competitive advantages commonly sought across polynucleotide treatment brands:
Unlike low-molecular-weight fragments that degrade rapidly, PNPURE™ utilizes high-molecular-weight polynucleotide chains. Once injected, these long polymer chains form a stable, three-dimensional physical scaffold within the extracellular matrix, providing prolonged bio-stimulation and sustained mechanical tension to native fibroblasts.
Residual immunogenic proteins in salmon-derived biologics can trigger localized inflammation or delayed hypersensitivity. The multi-stage PUNEXT™ purification protocol removes over 99.9% of cellular debris and non-DNA proteins, delivering an ultra-pure solution that supports safe repeat treatments across all skin types.
Fibroblast Activation: Binds to adenosine A2A receptors, initiating cascade pathways that stimulate Collagen I, Collagen III, and Elastin synthesis.
Endogenous Hydration: Restores dermal matrix integrity, enabling natural retention of endogenous Hyaluronic Acid without creating unnatural volume overcorrection.
Taken together, these attributes produce measurable clinical benefits: accelerated fibroblast activation, sustained ECM synthesis (collagen I/III, elastin), and durable hydration via indirect restoration of endogenous hyaluronic acid and barrier function.
When aesthetic clinics evaluate polynucleotide treatment brands, key performance parameters center on active PN concentration, molecular chain length, purification level, and targeted formulations. PNPURE™ is engineered to offer superior cost-to-performance and clinical outcomes in comparison to market benchmarks:
| Clinical / Technical Criteria | Market Standard PN Brands | PNPURE™ Product Line | Advantage for Aesthetic Clinics |
| PN Raw Material Purity | 90% – 95% average purity | >99% Ultra-High Purity (PUNEXT™) | Significantly lower risk of post-injection erythema or delayed immune reactions |
| Molecular Weight Range | 800 – 1000 kDa (Low to Mid) | 1260 – 1570 kDa (High-MW) | Longer-lasting 3D scaffold structure within the dermis for sustained collagenesis |
| Product Portfolio Versatility | Single general-purpose syringe | Differentiated (NeoSkin & NeoEye) | Precise rheology and active ingredients tailored for full-face vs. delicate periocular zones |
| Synergistic Actives (Eye Zone) | Pure PN only | PN + HA + Carnosine + Amino Acids | Multi-modal action addressing dark circles, fine lines, and oxidative stress simultaneously |

PNPURE™ is offered as two clinically differentiated preparations to meet distinct treatment needs while remaining under the single PNPURE™ brand promise.
Designed as the flagship product for full-face rejuvenation, PNPURE NeoSkin provides a higher active dose and is optimised to rebuild dermal architecture.
Key formulation highlights
PN concentration: 25 mg/mL (2.5%)
Molecular weight: 1260–1570 kDa
Presentation: 3 mL prefilled syringe; 30G needle
Indication: full-face skin quality improvement, post-procedure support
Clinical rationale and expected effects
· Dermal matrix reconstruction: high PN load supports collagen and elastin neosynthesis, improving firmness and contour.
· Hydration from within: by restoring dermal ECM and promoting HA synthesis, patients report measurable improvements in skin moisture and texture within days.
· Durability: NeoSkin’s formulation is designed to sustain fibroblast activation and ECM upregulation across multiple treatment sessions, offering both immediate and cumulative benefit.

The delicate periocular area requires a gentler, multi-functional approach. PNPURE NeoEye combines PN with supportive actives to hydrate, nourish and protect.
Key formulation highlights
PN concentration: 10 mg/mL
Molecular weight: 1260–1570 kDa
Actives: hyaluronic acid (HA), complex amino acids, carnosine (antioxidant dipeptide)
Presentation: 1 mL prefilled syringe; 30G needle
Indication: tear troughs, periorbital fine lines, and skin laxity around the eyes
Clinical rationale and expected effects
· Gentle yet effective: lower PN concentration and added HA allow targeted hydration with reduced irritation risk.
· Multimodal support: amino acids supply substrates for collagen/elastin production while carnosine provides antioxidant protection against photo-oxidative stress.
· Visible smoothing: patients typically notice decreased crepiness and improved skin clarity in the early post-treatment window, with progressive tightening thereafter.

Mechanistic overview (injection → regeneration)
1. Targeted placement: PNPURE™ is injected into the dermal plane where collagen, elastin and endogenous HA have diminished.
2. Scaffold formation: high-MW PN forms a transient matrix that supports cell migration and mechanical stability.
3. Biological activation: local fibroblasts are stimulated to proliferate and increase ECM synthesis; antioxidant and nutritive co-factors (NeoEye) reduce oxidative damage.
4. Functional improvement: improved dermal density, barrier restoration and hydration lead to smoother, firmer, more luminous skin.
Typical clinical milestones (multi-session protocol)
2–4 days after first session: perceptible smoothing and improved hydration.
2–3 weeks after second session: measurable improvement in tightness, reduced fine lines and clearer skin tone.
3–5 weeks after third session: enhanced lift and fuller appearance as dermal structure strengthens.
After fourth session (and maintenance): long-lasting radiance and resilience, with histological evidence of improved tissue architecture.

Internal preclinical and comparative histology assessments indicate that PNPURE™ produces earlier and more sustained fibroblast activation versus typical non-crosslinked HA. In clinical practice, this translates into durable improvements in skin quality beyond the immediate volumising effect of HA alone. Histological specimens show denser collagen networks and improved dermal thickness following PNPURE™ treatment series—findings that align with the regenerative concept underpinning the product family.
For visual proof of these regenerative results, explore our polynucleotides treatment before and after gallery showcasing authentic patient transformations.


Dermax provides factory-direct procurement and logistics support for aesthetic clinics, hospital networks, and authorized medical distributors worldwide.
Wholesale Pricing & Tiered Discounts: Volume-based pricing available for bulk clinic orders and regional distribution partners.
Supply Chain Assurance: Temperature-controlled sterile packaging with regional warehouse dispatch to ensure product integrity upon arrival.
Clinical Support Materials: Product dossiers, injection technique guides, and patient consultation assets available upon inquiry.
Request B2B Wholesale Quote & Product Dossier
PNPURE™ injectables maintain an outstanding safety profile attributable to the ultra-high purity PUNEXT™ refinement process. Mild, temporary post-injection reactions—such as localized edema, minor erythema, or small injection-site papules—typically resolve spontaneously within 24 to 48 hours.
Contraindications include active skin lesions or infections at the target site, known hypersensitivity to fish/salmon proteins, or autoimmune disorders under active flare.
